Home Pharmaceuticals Conjugate Vaccine Segment dominates Meningococcal Vaccine Market through 2031

Meningococcal Vaccine Market Size & Outlook, 2023-2031

Meningococcal Vaccine Market Size, Share & Trends Analysis Report By Vaccine Serotype (MenACWY, MenB and MenBC, MenC, MenA, MenAC), By Vaccine Type (Conjugate, Polysaccharide, Subcapsular), By End-User (Pediatric, Adult, Travelers) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRPH54183DR
Last Updated : Apr, 2023
Pages : 110
Author : Mitiksha Koul
Format : PDF, Excel

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Meningococcal Vaccine Market Introduction
    2. By Vaccine Serotype
      1. Introduction
        1. Vaccine Serotype By Value
      2. MenACWY
        1. By Value
      3. MenB and MenBC
        1. By Value
      4. MenC
        1. By Value
      5. MenA
        1. By Value
      6. MenAC
        1. By Value
    3. By Vaccine Type
      1. Introduction
        1. Vaccine Type By Value
      2. Conjugate
        1. By Value
      3. Polysaccharide
        1. By Value
      4. Subcapsular
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pediatric
        1. By Value
      3. Adult
        1. By Value
      4. Travelers
        1. By Value
    1. Introduction
    2. By Vaccine Serotype
      1. Introduction
        1. Vaccine Serotype By Value
      2. MenACWY
        1. By Value
      3. MenB and MenBC
        1. By Value
      4. MenC
        1. By Value
      5. MenA
        1. By Value
      6. MenAC
        1. By Value
    3. By Vaccine Type
      1. Introduction
        1. Vaccine Type By Value
      2. Conjugate
        1. By Value
      3. Polysaccharide
        1. By Value
      4. Subcapsular
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pediatric
        1. By Value
      3. Adult
        1. By Value
      4. Travelers
        1. By Value
    5. U.S.
      1. By Vaccine Serotype
        1. Introduction
          1. Vaccine Serotype By Value
        2. MenACWY
          1. By Value
        3. MenB and MenBC
          1. By Value
        4. MenC
          1. By Value
        5. MenA
          1. By Value
        6. MenAC
          1. By Value
      2. By Vaccine Type
        1. Introduction
          1. Vaccine Type By Value
        2. Conjugate
          1. By Value
        3. Polysaccharide
          1. By Value
        4. Subcapsular
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pediatric
          1. By Value
        3. Adult
          1. By Value
        4. Travelers
          1. By Value
    6. Canada
    1. Introduction
    2. By Vaccine Serotype
      1. Introduction
        1. Vaccine Serotype By Value
      2. MenACWY
        1. By Value
      3. MenB and MenBC
        1. By Value
      4. MenC
        1. By Value
      5. MenA
        1. By Value
      6. MenAC
        1. By Value
    3. By Vaccine Type
      1. Introduction
        1. Vaccine Type By Value
      2. Conjugate
        1. By Value
      3. Polysaccharide
        1. By Value
      4. Subcapsular
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pediatric
        1. By Value
      3. Adult
        1. By Value
      4. Travelers
        1. By Value
    5. U.K.
      1. By Vaccine Serotype
        1. Introduction
          1. Vaccine Serotype By Value
        2. MenACWY
          1. By Value
        3. MenB and MenBC
          1. By Value
        4. MenC
          1. By Value
        5. MenA
          1. By Value
        6. MenAC
          1. By Value
      2. By Vaccine Type
        1. Introduction
          1. Vaccine Type By Value
        2. Conjugate
          1. By Value
        3. Polysaccharide
          1. By Value
        4. Subcapsular
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pediatric
          1. By Value
        3. Adult
          1. By Value
        4. Travelers
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Vaccine Serotype
      1. Introduction
        1. Vaccine Serotype By Value
      2. MenACWY
        1. By Value
      3. MenB and MenBC
        1. By Value
      4. MenC
        1. By Value
      5. MenA
        1. By Value
      6. MenAC
        1. By Value
    3. By Vaccine Type
      1. Introduction
        1. Vaccine Type By Value
      2. Conjugate
        1. By Value
      3. Polysaccharide
        1. By Value
      4. Subcapsular
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pediatric
        1. By Value
      3. Adult
        1. By Value
      4. Travelers
        1. By Value
    5. China
      1. By Vaccine Serotype
        1. Introduction
          1. Vaccine Serotype By Value
        2. MenACWY
          1. By Value
        3. MenB and MenBC
          1. By Value
        4. MenC
          1. By Value
        5. MenA
          1. By Value
        6. MenAC
          1. By Value
      2. By Vaccine Type
        1. Introduction
          1. Vaccine Type By Value
        2. Conjugate
          1. By Value
        3. Polysaccharide
          1. By Value
        4. Subcapsular
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pediatric
          1. By Value
        3. Adult
          1. By Value
        4. Travelers
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Vaccine Serotype
      1. Introduction
        1. Vaccine Serotype By Value
      2. MenACWY
        1. By Value
      3. MenB and MenBC
        1. By Value
      4. MenC
        1. By Value
      5. MenA
        1. By Value
      6. MenAC
        1. By Value
    3. By Vaccine Type
      1. Introduction
        1. Vaccine Type By Value
      2. Conjugate
        1. By Value
      3. Polysaccharide
        1. By Value
      4. Subcapsular
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pediatric
        1. By Value
      3. Adult
        1. By Value
      4. Travelers
        1. By Value
    5. UAE
      1. By Vaccine Serotype
        1. Introduction
          1. Vaccine Serotype By Value
        2. MenACWY
          1. By Value
        3. MenB and MenBC
          1. By Value
        4. MenC
          1. By Value
        5. MenA
          1. By Value
        6. MenAC
          1. By Value
      2. By Vaccine Type
        1. Introduction
          1. Vaccine Type By Value
        2. Conjugate
          1. By Value
        3. Polysaccharide
          1. By Value
        4. Subcapsular
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pediatric
          1. By Value
        3. Adult
          1. By Value
        4. Travelers
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Vaccine Serotype
      1. Introduction
        1. Vaccine Serotype By Value
      2. MenACWY
        1. By Value
      3. MenB and MenBC
        1. By Value
      4. MenC
        1. By Value
      5. MenA
        1. By Value
      6. MenAC
        1. By Value
    3. By Vaccine Type
      1. Introduction
        1. Vaccine Type By Value
      2. Conjugate
        1. By Value
      3. Polysaccharide
        1. By Value
      4. Subcapsular
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pediatric
        1. By Value
      3. Adult
        1. By Value
      4. Travelers
        1. By Value
    5. Brazil
      1. By Vaccine Serotype
        1. Introduction
          1. Vaccine Serotype By Value
        2. MenACWY
          1. By Value
        3. MenB and MenBC
          1. By Value
        4. MenC
          1. By Value
        5. MenA
          1. By Value
        6. MenAC
          1. By Value
      2. By Vaccine Type
        1. Introduction
          1. Vaccine Type By Value
        2. Conjugate
          1. By Value
        3. Polysaccharide
          1. By Value
        4. Subcapsular
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pediatric
          1. By Value
        3. Adult
          1. By Value
        4. Travelers
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Meningococcal Vaccine Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. GlaxoSmithKline Plc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Sanofi S.A.
    3. Pfizer Inc.
    4. Serum Institute of India Pvt. Ltd
    5. Bio-Manguinhos
    6. Bio-Med Pvt. Limited
    7. Chongqing Zhifei Biological Products Co. Ltd.
    8. Hualan Biological Engineering Inc.
    9. Incepta Pharmaceuticals Ltd.
    10. Walvax Biotechnology Co. Ltd
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Available for purchase with detailed segment data, forecasts, and regional insights.

Get This Report

Download Free Sample

Note: Please ensure you provide an active email address as we will be sending sample details via email.
The button will be active once the above form is filled

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on :

Address:
Office 515 A, Amanora Chambers,
Amanora Park Town, Hadapsar,
Pune 411028, Maharashtra, India.
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
DMCA.com Protection Status
Secure Payments:
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.